Xenetic Biosciences- Warrants (19/07/2024) Return on Equity

Xenetic Biosciences- Warrants (19/07/2024)'s return on equity stands at -40.76%. That is below the Healthcare sector average of 21.67%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Xenetic Biosciences- Warrants (19/07/2024) sits lower the Healthcare benchmark (21.67%) with a ROE of -40.76%. That is roughly 288.1% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A ROE of -40.76% for Xenetic Biosciences- Warrants (19/07/2024) means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how Xenetic Biosciences- Warrants (19/07/2024)'s ROE evolved across reporting periods, while the comparison chart places XBIOW next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, ROE is commonly used to spot outliers. Xenetic Biosciences- Warrants (19/07/2024)'s reading of -40.76% (sector avg 21.67%) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.